Choppin A, Berry C N
Cardiovascular Department, Synthélabo Recherche, Bagneux, France
Thromb Res. 1995 May 15;78(4):293-302. doi: 10.1016/0049-3848(95)00062-v.
Seven compounds having varying affinities for peripheral benzodiazepine (p sites) were evaluated in vitro as inhibitors of arachidonic acid-induced rabbit platelet aggregation and thromboxane B2 (TXB2) synthesis. With the exception of flumazenil, all compounds inhibited both parameters with IC50 values ranging from 0.19 to 3.5 microM, with a significant correlation between the inhibition of aggregation and the synthesis of thromboxane B2. The antiaggregatory effect was stereoselective, and inhibition was increased when cellular penetration was favoured by increasing the volume of the organic solvent. The order of potency these compounds is consistent with an effect at intracellular p sites (Ro5-4864 > PK14067 > PK 11195 >> PK 14068 > or = clonazepam > or = diazepam >>> flumazenil). However, the correlation between the aggregation inhibition and the synthesis of TXB2 suggests that microsomal cyclooxygenase may be the intracellular target of these ligands. We therefore propose that this enzyme possesses a site for benzodiazepine ligands which may share certain characteristics with the peripheral benzodiazepine receptor.
对七种对外周苯二氮䓬(p位点)具有不同亲和力的化合物进行了体外评估,以确定它们作为花生四烯酸诱导的兔血小板聚集和血栓素B2(TXB2)合成抑制剂的活性。除氟马西尼外,所有化合物均抑制这两个参数,IC50值范围为0.19至3.5微摩尔,聚集抑制与血栓素B2合成之间存在显著相关性。抗聚集作用具有立体选择性,当通过增加有机溶剂体积促进细胞穿透时,抑制作用增强。这些化合物的效力顺序与细胞内p位点的作用一致(Ro5-4864 > PK14067 > PK 11195 >> PK 14068 > 或 = 氯硝西泮 > 或 = 地西泮 >>> 氟马西尼)。然而,聚集抑制与TXB2合成之间的相关性表明,微粒体环氧化酶可能是这些配体的细胞内靶点。因此,我们提出该酶具有一个苯二氮䓬配体结合位点,该位点可能与外周苯二氮䓬受体具有某些共同特征。